European Medicines Agency (EMA) Greenlights Mitochon Pharmaceuticals to Initiate Phase I/IIa Biomarker Study in Neurodegenerative Diseases
- katie8288
- Jan 11, 2024
- 1 min read
BLUE BELL, Pa.--(BUSINESS WIRE)--Mitochon Pharmaceuticals today announced that it was awarded approval from EMA to begin enrollment for a Phase I/IIa biomarker study in Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Huntington’s Disease (HD) and Alzheimer’s Disease (AD) participants. Mitochon’s MP101, a once-daily, oral brain penetrant mitochondrial stimulator, that improves central nervous system survival and function will be used in this 14-day pilot study. The aim of the study is to show safety in the target patient populations and demonstrate meaningful changes in disease specific biomarkers. Successful completion of this study will provide the basis for long term Phase IIb clinical studies in ALS, Secondary & Primary Progressive MS, HD, and AD patients, leading to the first mitochondrial specific therapy for these truly insidious diseases.
I was diagnosed with Amyotrophic Lateral Sclerosis (ALS) four years ago. For over two years, I relied on various prescribed treatments, but unfortunately, the symptoms continued to progress. The muscle weakness became more noticeable, and my coordination and mobility started to decline more quickly than I expected.Last year, feeling desperate for anything that might help, I decided to try a herbal treatment program from NaturePath Herbal Clinic. I was skeptical at first, but after a few months, I felt some changes my movements seemed a bit smoother, the stiffness less overwhelming, and I felt a little steadier on my feet. I also experienced moments where my energy and confidence felt improved compared to before.This experience has been meaningful for me…